HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -15.34% | 12.46% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -15.34% | 12.46% | |||
| Cost of Revenue | -2.03% | 12.29% | |||
| Gross Profit | -20.55% | 12.53% | |||
| SG&A Expenses | 2.59% | -6.24% | |||
| Depreciation & Amortization | 1.34% | -0.87% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.81% | 0.49% | |||
| Operating Income | -1,034.60% | 117.25% | |||
| Income Before Tax | -15.79% | 49.63% | |||
| Income Tax Expenses | 100.31% | -3,705.88% | |||
| Earnings from Continuing Operations | -72.06% | 65.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -72.06% | 65.93% | |||
| EBIT | -1,034.60% | 117.25% | |||
| EBITDA | -35.91% | 25.26% | |||
| EPS Basic | -83.50% | 67.95% | |||
| Normalized Basic EPS | -23.72% | 52.62% | |||
| EPS Diluted | -83.50% | 67.95% | |||
| Normalized Diluted EPS | -23.72% | 52.62% | |||
| Average Basic Shares Outstanding | -6.30% | 6.28% | |||
| Average Diluted Shares Outstanding | -6.30% | 6.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||